Kymera Therapeutics, Inc. (KYMR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$144.1M
Cash & Equivalents
$88.8M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$9,817M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase1 Readout | — |
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07217015 | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | PHASE2 | Active Not Recruiting | 200 |
| NCT07323654 | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | PHASE2 | Recruiting | 264 |
| NCT07677059 | A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study | PHASE2 | Recruiting | 264 |
| NCT07412288 | First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants | PHASE1 | Recruiting | 96 |
| NCT07629336 | SAR447971 First-in-human Study | PHASE1 | Recruiting | 114 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-25 | 8-K | Kymera Therapeutics, Inc. (KYMR) (CIK 0001815442) - EX-99.1 | EDGAR |